|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Novo Nordisk
| | | Phone: | (609) 987-5800 | Year Established: | 1923 | Ticker: | NVO | Exchange: | NYSE | Main Contact: | Phil Fornecker, CPA, VP, Strategic Business Operations | | Other Contacts: | Andy Ajello, Senior VP, U.S. National Diabetes Sales Eddie Li, Ph.D., VP, Regulatory Affairs Karsten Knudsen, VP, Finance & Information Technology Alan C. Moses, MD, Senior VP, Global CMO Camille Lee, Senior VP, Diabetes Marketing Anne Phillips, MD, Senior VP, Clinical, Medical & RA, North America Jerzy Gruhn, President
| | Company Description | Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. | |
|
|
|
|
|